Enhanced cell growth, production, and mAb quality produced in Chinese hamster ovary-K1 cells by supplementing polyamine in the media

Kang, Da Eun; An, Yeong Bin; Kim, Yeunju; Ahn, Seawon; Kim, Young Jin; Lim, Jung Soo; Ryu, S.; Choi, Hyoju; Yoo, Jiseon; You, Weon‐Kyoo; Lee, Dong-Yup; Park, Junsoo; Hong, Minsun; Lee, Gyun Min; Baik, Jong Youn; Hong, Jong Kwang

doi:10.1007/s00253-023-12459-7

Cited by 3 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, nearly 70% of approved RTPs are produced from CHO cell system (Kang et al 2023 ; Stolfa et al 2018 ; Wang and Guo 2020 ). After continuous domestication and modification of CHO cells, subtypes such as CHO-K1, CHO-S, CHO-DBX11, and CHO-DG44 have been obtained (MacDonald et al 2022b ).…”

Section: Introductionmentioning

confidence: 99%

Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells

Geng,

Zhao,

Zhang

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Mammalian cell lines are frequently used as the preferred host cells for producing recombinant therapeutic proteins (RTPs) having post-translational modified modification similar to those observed in proteins produced by human cells. Nowadays, most RTPs approved for marketing are produced in Chinese hamster ovary (CHO) cells. Recombinant therapeutic antibodies are among the most important and promising RTPs for biomedical applications. One of the issues that occurs during development of RTPs is their degradation, which caused by a variety of factors and reducing quality of RTPs. RTP degradation is especially concerning as they could result in reduced biological functions (antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity) and generate potentially immunogenic species. Therefore, the mechanisms underlying RTP degradation and strategies for avoiding degradation have regained an interest from academia and industry. In this review, we outline recent progress in this field, with a focus on factors that cause degradation during RTP production and the development of strategies for overcoming RTP degradation. Key points • The recombinant therapeutic protein degradation in CHO cell systems is reviewed. • Enzymatic factors and non-enzymatic methods influence recombinant therapeutic protein degradation. • Reducing the degradation can improve the quality of recombinant therapeutic proteins.

show abstract